ERBB2 and neoplasm: Recent literature highlights that patients with minimal residual disease exhibit significantly better outcomes compared to those with extensive residual tumor burden, particularly in aggressive subtypes such as triple-negative breast cancer (TNBC) and HER2-positive disease [36].